and fibroblasts, and increased deposition of extracellular ease (COPD) include airway and vascular remodeling, the momatrix (3). In addition, advanced COPD leads to pathologic lecular mechanisms of which are poorly understood. We aschanges in the pulmonary circulation (4, 5) . At least part including the lung (9), fibroblast growth factors (FGFs) Chronic obstructive pulmonary disease (COPD) is a global may well play a pivotal role in airway and VW remodeling health problem with increasing morbidity and mortality (1). (7, 8) . FGFs exert their biologic effects via binding to four One of the major causal factors is tobacco smoking (2).
tion of pulmonary arteries, arterioles, and veins, the medial including the lung (9) , fibroblast growth factors (FGFs) Chronic obstructive pulmonary disease (COPD) is a global may well play a pivotal role in airway and VW remodeling health problem with increasing morbidity and mortality (1) . (7, 8) . FGFs exert their biologic effects via binding to four One of the major causal factors is tobacco smoking (2) .
high-affinity FGF transmembrane tyrosine-kinase receptors However, only ten percent of all smokers develop symptom-(FGFR) (9) . Distinct FGF subtypes bind with different afatic COPD. The causes of this variability in response of the finity to the various FGFR . Alternative splicing and reguairways and lung parenchyma to tobacco smoke exposure lated protein trafficking further modulate the intracellular have remained largely unclear. One of the key pathologic events and resultant response initiated by FGF ligandfeatures of COPD is thickening of airway walls as a result receptor interaction (9) . In the lung as well as in the vascular of inflammation, hyperplasia of airway smooth muscle cells system, FGFs have been implicated in several pathologic conditions. FGF-1 and FGFR-1 were shown to be upregulated during the development of lung fibrosis (10) . FGF-2 (Received in original form December 15, 2000 and in revised form May 6, 2002) and platelet-derived growth factor (PDGF) have been impli- 75%, a reversibility in FEV 1 р 12% of predicted after 400 g inhaled salbutamol, and a transfer factor for carbon monoxide (diffusion capacity) per liter alveolar volume (K co ) р 80% of predicted value.
Materials and Methods
of staining obtained with a series of dilutions, which produced Group without COPD. Thirteen subjects were assigned to the specific and easily visible signals on paraffin sections made from group without COPD on the basis of the following data; a FEV 1 Ͼ the same control tissue before performing the staining protocol 85% before bronchodilatation, FEV 1 /FVC ratio Ͼ 85%, and reon all sections. To avoid day-to-day variations in staining intensitversibility in FEV 1 р 12% of predicted after 400 g salbutamol ies, the incubations of all specimens with each antibody were perinhalation. To exclude accompanying lung disease leading to a formed in one single run. Sections were deparaffinized and rehyrestrictive function disorder, the total lung capacity of each subject drated before incubation with specific mouse monoclonal and included in the study was over 80% of the predicted values (16) .
affinity-purified antibodies against FGF-1 (1:2000 dilution), FGF-2 Clinical data of all patients were examined for possible comor-(1:200 dilution) and FGFR-1 (1:2000 dilution). The mouse IgG1 bidity and medication usage. All patients were free of symptoms antibody against human FGF-1 was raised using a synthetic peptide of upper respiratory tract infection and none received antibiotics corresponding to the internal 61-99 amino acid sequence, whereas perioperatively. None of the patients received glucocorticosteroids the mouse IgG2b antibody was raised against a synthetic peptide in the 3 mo before operation; four patients received oral glucocorticorresponding to the 16 amino acids from the C-terminus of human costeroids perioperatively. In addition to the rigorous criteria FGFR-1, as described previously (17, 18). FGF-2 was a mouse based on lung function parameters, microscopic exclusion criteria (IgG1 isotype) monoclonal antibody raised against human FGF-2 was also applied in the selection of patients for this study. After (molecular weight: 18-24 kD), which was procured from Transducthe selection based on lung function, all the lung tissues were tion Laboratories (Lexington, KY). Antihuman mouse monoclonal subsequently examined histologically by two experienced lung paantibodies against ␣-smooth muscle actin (␣-SMA), Ki-67 and thologists using the following exclusion criteria: (i ) presence of FGF-2 were purchased from NeoMarkers (Clone 1A4; Fremont, tumor in the lung tissue specimen; (ii) presence of poststenotic CA), from Biogenex (San Ramon, CA) and from Transduction pneumonia in the specimen; (iii) fibrosis of lung tissue; and (iv) Laboratories, respectively. To block nonspecific binding, sections obstruction of the main bronchus of the resection specimen by were preincubated with 10% normal goat serum diluted in 5% tumor (14, 15) .
BSA in PBS (pH 7.4). Subsequently, sections were incubated overnight at 4ЊC with the primary antibodies (FGF-1 and FGFR-1) diluted appropriately, or for 1 h at room temperature in the case
Pulmonary Function Tests
of ␣-SMA (1:1000 dilution). Secondary biotinylated anti-immunoglobulins (Multilink, 1:75 dilution; Biogenex) and tertiary streptaAll pulmonary function tests were performed within the 3 months vidin conjugated alkaline phosphatase (Label 1:50 dilution; Biobefore surgery. FEV 1 and FVC were measured by spirometry, total genex) were used to enhance the detection sensitivity. Color was lung capacity, and residual volume with the closed circuit helium developed using new fuchsin, while endogenous alkaline phosphadilution test and the K co using the single breath-holding technique, tase activity was inhibited by 0.01 M levamisole. as described by Quanjer and coworkers (16) . Lung function data FGF-2 and Ki-67 immunostaining was performed on serial secand other patient characteristics are shown in Table 1 .
tions after antigen retrieval by boiling in 10 mM citrate buffer (pH 6.0) for 10 min in a microwave oven. Sections were preincubated with 10% normal goat serum in 5% BSA/PBS, followed by incuba-
Immunohistochemistry
tion with primary antibody (1:50 dilution) overnight at 4ЊC. Slides Sections of paraffin-embedded lung tissue were cut at 4 m, were rinsed in PBS, incubated for 30 min with peroxidase conjumounted on Super Frost Plus microscopic slides (Menzel-Glä ser, gated streptavidin at a dilution of 1:50 (Biogenex). Subsequently, Braunschweig, Germany) and processed for immunohistochemissections were colored using 0.025% 3,3-diaminobenzidine (Sigma, try. Serial sections were used for immunostaining of FGF-1, FGF-2, St. Louis, MO) in 0.01 molar PBS, containing 0.03% hydrogen and FGFR-1 using human-specific antibodies. The optimal diluperoxide. Slides were counterstained with Mayer's hematoxylin. Positive controls consisted of human breast carcinoma and placentions for all antibodies were identified by examining the intensity tal tissue. The optimal dilutions for all antibodies were identified inside diameter [ID] ) and in the endothelium, VSM, and adventitial area of large (Ͼ 200 m ID) pulmonary arteries. by examining the intensity of staining obtained with a series of dilutions, which produced specific and easily visible signals on paraffin sections derived from the same control tissue. Slides were mounted and staining results were systematically investigated (see
Video Image Analysis below). Negative controls consisted of omission of the primary
In addition, video image analysis was performed for ␣-SMA stainantibody.
ing using Leica Qwin system version 3.0 (Leica B.V., Rijswijk, The Netherlands). Twenty digital images (736 ϫ 574 pixels) from each section were taken using a video camera. ID of blood vessels was
Semiquantitative Analysis
derived as a mean of measured vertical and horizontal diameters. In our study, we excluded those vessels with a vertical to horizontal All tissues were analyzed in a blinded fashion in random order by ID ratio Ͼ 3. Based on the ID, pulmonary vessels were grouped two independent observers who were unaware of the clinical data into four sizes (50-100 m, 100-200 m, 200-400 m and Ͼ 400 of the case under study. Semiquantitative analysis was performed m). VW area, ␣-SMA stained area and vessel ID were measured. using an arbitrary visual scale with grading scores of 0, 1, 2, and 3
Measurements were expressed as percentages of staining per VW representing no, weak, moderate and intense staining, respectively (␣-SMA/VW area ), for VW area corrected for ID (VW area /ID) and (14, 15) . Errors within and between observers were assessed by ␣-SMA staining, also corrected for lumen diameter (␣-SMA area /ID). correlating the expression scores using Pearson's analysis, which indicated a very high correlation, ranging from 0.8 to 0.9. Microphotographs in Figures 1A to 1D staining is presented in Figure 3 . In subjects with COPD, The clinical and lung function characteristics of all subjects we observed significantly increased (P Ͻ 0.02) expression included in the study are listed in Table 1 . . In contrast to FGF-1, the expression of FGF-2 was the group with COPD, residual volume was increased, elevated in the group with COPD, but only in the small whereas K co was reduced (P Ͻ 0.005). The subjects in the vessels with an ID Ͻ 200 m, where it was increased in two groups did not differ significantly with respect to age, endothelial (P Ͻ 0.007) and medial smooth muscle (P Ͻ total lung capacity, reversibility in FEV 1 , smoking status (pack-years), or previous steroid usage (Table 1) . 0.001) cells ( Figure 3B ). The staining scores of FGF-1, FGF-2, and FGFR-1 expres- Figure 5 . The expression of FGFR-1 was significantly elesion in patients with COPD and those without COPD were vated in medial smooth muscle cells of large vessels (P Ͻ analyzed using Pearson's test. For FGF-1, we observed a 0.04) in the group with COPD as compared with the group weak but significant inverse correlation (r ϭ Ϫ0.39, P ϭ without COPD, whereas the staining for the receptor in 0.038) between staining score and FEV 1 in the medial VSM the intimal endothelium remained unaltered. Moreover, in of vessels Ͼ 200 m in ID ( Figure 8A ). In addition, there contrast to the FGF-1 expression in small vessels in patients was a significant inverse correlation of FGF-2 staining scores with COPD, we found significantly higher expression levels in both endothelium (r ϭ Ϫ0.44, P ϭ 0.002) and medial of the receptor (P Ͻ 0.05) in medial smooth muscle of small VSM (r ϭ Ϫ0.55, P Ͻ 0.0001) of vessels Ͻ 200 m in ID vessels ( Figure 5 ).
with FEV 1 (Figures 8B and 8C ). However, in vessels Ͼ 200 m in ID, no significant correlation between FGF-2 expresAssessment of Vascular Remodeling sion and FEV 1 was found (data not shown). Surprisingly, To examine pulmonary vascular remodeling as evidenced in staining scores for FGFR-1 were not significantly correlated variations in wall thickness and muscular medial thickness, with FEV 1 (data not shown). When considering the associavideo image analysis was performed using ␣-SMA immunotion between FEV 1 and medial hypertrophy (VW area /ID rastaining. Four separate groups with vessels of 50-100, 100-tio), we observed a significant inverse correlation of Ϫ0.42 200, 200-400 and Ͼ 400 m ID, respectively, were analyzed (P ϭ 0.007) for vessels Ͼ 200 m ID ( Figure 8D ). However, (Figure 6 ). Measurements (mean Ϯ SEM) were expressed no significant correlation could be established between as VW area /ID, ␣-SMA area /ID, or percentage ␣-SMA staining FEV 1 and VW area /ID ratio for the vessels Ͻ 200 m ID (r ϭ per VW area that represents the volume fraction for smooth Ϫ0.10, P Ͼ 0.10). muscle staining (␣-SMA/VW area ). The graphic representation of VW is presented in Figure 7 . A significant increase In this study we have found that COPD is associated with an increase in the expression of FGF-2 in small pulmonary (57.9 Ϯ 2.4 versus 44.7 Ϯ 3.2, P Ͻ 0.001) and Ͼ 400 m (75.6 Ϯ 2.6 versus 56.8 Ϯ 5.9, P ϭ 0.011) ( Figure 7A FGF-2 expression in both endothelium and VSM of small vessels. In addition, an inverse correlation of FEV 1 with medial thickening was found in pulmonary vessels of larger caliber, indicating that the degree of pulmonary vascular remodeling is related to the severity of obstructive lung function defect. Several studies have commented on the importance of structural and functional abnormalities in the pulmonary vasculature of patients with COPD. Hypoxia is known to induce prompt and severe vasoconstriction in the pulmonary vasculature, and sustained lung tissue hypoxia, as results from obstructive lung disease such as COPD, leads to pulmonary hypertension (4, 19) . Hypoxic vasoconstriction is considered to represent one of the major contributing factors of pulmonary hypertension and right-sided heart failure in COPD and other chronic pulmonary diseases (4, 19) . In addition, emphysema, accompanied by loss of elastic recoil, increased pulmonary pressure, and destruction of part of the pulmonary microvasculature may contribute to VW thickening in patients with COPD and non-COPD peripheral regions of the lungs of patients with COPD, we also observed FGF-1 in adventitia and FGF-2 immunoreactivity in the nuclei of medial smooth muscle and endothelial cells, suggesting a potential role of the FGF-FGFR system in vascular remodeling in patients with COPD. FGF family members are implicated in tissue remodeling in a wide variety of pathophysiologic conditions, including systemic hypertension, ischemic heart disease, and interstitial lung fibrosis (10, 12, 26, 27 ). Barrios and coworkers (10) showed FGF-1 and FGFR-1 expression in experimentally induced pulmonary fibrosis. Becerril and colleagues found that FGF-1 expression in the lung fibroblasts results in downregulation of collagen synthesis and upregulation of collagenases, which may protect against fibrosis (28) . However, increased FGF-2 and FGFR-1 expression in vascular smooth muscle cells in vitro in response to vascular injury has been shown to be associated with extracellular matrix remodeling, cellular proliferation, downregulation of collagen type I, and upregulation of collagenase MMP-1 (29). Our findings of upregulated FGF-1, FGF-2, and FGFR-1 expression could indicate that such compensatory mechanisms are active in COPD because smoking has been sug- suggesting novel mechanisms for the action of FGF-2 (30). We used expression of smooth muscle marker ␣-SMA
In this study, we show that FGF-2 is localized in the nucleus (24) to investigate whether the ␣-SMA/VW area ratio of of endothelial and VSM cells and that its expression is smooth muscle in the VW had changed during the progresincreased in pulmonary vessels with diameter Ͼ 200 m in sion of COPD. Surprisingly, the ratio remained unchanged.
patients with COPD, indicating a role for this growth factor Approximately 42% of cells in all vessels stained positive in vascular remodeling. We also show that in patients with for ␣-SMA, indicating that the increase in wall thickness COPD, the expression of FGF-2 was upregulated in vessels could be attributed to the deposition of extracellular matrix with an ID of Ͼ 200 m. Bryant and coworkers (13) recently proteins and the medial accumulation of other cells, such found that administration of FGF-2 could inhibit internal as inflammatory cells and fibroblasts. Recently, we found luminal area decrease and wall thickening in response to specific staining for extracellular matrix proteins, like fialtered blood flow; furthermore, this inhibitory effect could bronectin and collagen subtypes, in the intimal vascular be blocked by anti-FGF-2 neutralizing antibodies. Our cells of these pulmonary vessels, indicating ongoing intimal findings suggest that FGF-2 plays an important role in the fibrosis in patients with COPD (data not shown). Taken response to increased pressure in the pulmonary vasculature together, the data from this study indicate that vascular of patients with COPD. Several studies on hypoxia-induced remodeling in patients with COPD could be a contributing pulmonary hypertension have shown that increased smooth event in the pathogenesis of pulmonary hypertension in muscle mass develops as a result of hypertrophy and hyperthese patients. Furthermore, the observed changes in the plasia of pre-existing smooth muscle cells, or results from intimal fibrosis as well as medial thickening could narrow differentiation of fibroblasts recruited to the media from the vessel caliber and may eventually lead to more severe the adventitia (24, 31) . It is likely that such mechanisms of vascular obstruction in patients with COPD. vascular smooth muscle mass increase are operational in Members of the FGF family FGF-1, FGF-2, and FGFR-1 COPD-related vascular remodeling. are constitutively expressed in normal human lungs, particu-
In vivo and in vitro data indicate that smooth muscle larly in airway epithelium and monocytes, and are localized cells, and their cross-talk with the endothelium, myofiin the intima and media of pulmonary vessels (25). Pulmobroblasts, and inflammatory cells via growth factors and nary expression patterns of FGF-1, FGF-2, and FGFR-1, cytokines, are major contributing factors to vascular remodas found in our study, are in agreement with results obtained eling during different pathophysiologic conditions (24, 28, 32, 33). Furthermore, inflammation, a well-established facby Hughes and Hall (25) in normal lungs. However, in the
